Analyst Mike Kratky from Leerink Partners reiterated a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at $77.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Mike Kratky’s rating is based on a combination of factors, primarily focusing on the recent performance and future outlook of Edwards Lifesciences. While the company reported a strong fourth quarter with sales exceeding expectations, the guidance for fiscal year 2025 remained unchanged. This lack of upward revision in outlook may temper investor excitement despite the positive quarterly results.
Moreover, Kratky notes that ongoing capacity constraints could hinder growth, particularly in the Transcatheter Aortic Valve Replacement (TAVR) segment. Although TAVR sales slightly surpassed projections, hospital capacity issues continue to pose a challenge. The anticipated impact of these constraints, especially with upcoming product launches, contributes to the decision to maintain a Hold rating, reflecting a balanced view of potential risks and rewards.
In another report released yesterday, Evercore ISI also maintained a Hold rating on the stock with a $73.00 price target.
EW’s price has also changed moderately for the past six months – from $65.540 to $75.820, which is a 15.69% increase.